Chris Howerton
Stock Analyst at Jefferies
(2.45)
# 2,410
Out of 4,761 analysts
75
Total ratings
43.33%
Success rate
12.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $5.06 | +58.10% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $23.77 | +232.42% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $2.04 | +96.08% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $1 | $0.57 | +74.61% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $2.13 | +16,425.82% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $8.44 | +8,430.81% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $2.10 | -76.19% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $10.08 | -0.79% | 1 | Feb 8, 2023 | |
| MEIP MEI Pharma | Downgrades: Underperform | $8 → $2 | $2.60 | -23.08% | 3 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $8.41 | +30.80% | 3 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $70 → $40 | $27.52 | +45.35% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $34.56 | +76.50% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $137.75 | -34.66% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.43 | +170.88% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $126 | $1.38 | +9,030.43% | 1 | Dec 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.10 | +1,718.18% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $22.46 | +193.86% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $0.16 | +18,661.73% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $11.63 | +89.17% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.17 | +867.74% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $1.38 | +1,494.20% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $0.96 | +2,302.09% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $19.95 | +5.26% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $4 → $29 | $0.80 | +3,509.21% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.30 | +4,515.38% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $63.54 | -74.82% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $38.75 | -30.32% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.21 | +11,567.48% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $5.06
Upside: +58.10%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $23.77
Upside: +232.42%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $2.04
Upside: +96.08%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $1
Current: $0.57
Upside: +74.61%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $2.13
Upside: +16,425.82%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $8.44
Upside: +8,430.81%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $2.10
Upside: -76.19%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $10.08
Upside: -0.79%
MEI Pharma
Feb 8, 2023
Downgrades: Underperform
Price Target: $8 → $2
Current: $2.60
Upside: -23.08%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $8.41
Upside: +30.80%
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $27.52
Upside: +45.35%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $34.56
Upside: +76.50%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $137.75
Upside: -34.66%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.43
Upside: +170.88%
Dec 13, 2021
Maintains: Buy
Price Target: $101 → $126
Current: $1.38
Upside: +9,030.43%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $1.10
Upside: +1,718.18%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $22.46
Upside: +193.86%
Aug 24, 2021
Initiates: Buy
Price Target: $30
Current: $0.16
Upside: +18,661.73%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $11.63
Upside: +89.17%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $2.17
Upside: +867.74%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $1.38
Upside: +1,494.20%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $0.96
Upside: +2,302.09%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $19.95
Upside: +5.26%
Aug 11, 2020
Upgrades: Buy
Price Target: $4 → $29
Current: $0.80
Upside: +3,509.21%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.30
Upside: +4,515.38%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $63.54
Upside: -74.82%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $38.75
Upside: -30.32%
May 26, 2020
Initiates: Buy
Price Target: $24
Current: $0.21
Upside: +11,567.48%